Synthroid and Bupropion Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Synthroid and Bupropion?

The Synthroid, bupropion interaction is pharmacodynamic rather than pharmacokinetic at its core. Bupropion inhibits norepinephrine and dopamine reuptake (NDRI class) and simultaneously inhibits CYP2D6, the enzyme responsible for metabolizing roughly 25% of prescribed drugs. Levothyroxine is not a primary CYP2D6 substrate, so the enzyme inhibition does not meaningfully change levothyroxine blood levels. The real concern is additive physiological stress on the cardiovascular and central nervous systems.

Pharmacodynamic Convergence

Excess thyroid hormone increases sympathetic tone. Heart rate rises, blood pressure climbs, and myocardial oxygen demand grows. Bupropion compounds this by blocking norepinephrine reuptake, raising circulating catecholamine effect at adrenergic receptors. A 2020 review in Pharmacology & Therapeutics confirmed that norepinephrine-potentiating agents combined with thyrotoxic states produce additive tachycardia and a measurable increase in arrhythmia risk [1].

Seizure Threshold Reduction

Bupropion's Black Box Warning covers seizure risk explicitly. The FDA-approved labeling for bupropion states that the seizure incidence at 300 mg/day sustained-release is approximately 0.1%, rising to 0.4% at the maximum approved dose [2]. Levothyroxine, when dosed to produce supraphysiologic free T4, lowers the seizure threshold independently. A 2017 case series in Thyroid (N=14) documented new-onset seizures in patients receiving aggressive TSH-suppressive levothyroxine therapy for differentiated thyroid cancer [3]. Combining both drugs in a patient with undetected subclinical hyperthyroidism raises that risk further.

CYP2D6 Inhibition: Indirect Consequences

Bupropion's inhibition of CYP2D6 does not alter levothyroxine metabolism directly. It does, however, raise plasma concentrations of any co-administered CYP2D6 substrate the patient takes, including many beta-blockers used to control thyroid-related tachycardia (e.g., metoprolol, which is a primary CYP2D6 substrate). If a clinician adds metoprolol to manage palpitations from the levothyroxine, bupropion combination, bupropion may double metoprolol exposure, risking bradycardia or AV block [4].

Severity Classification Across Drug Interaction Databases

No single DDI database assigns the same severity tier to this pair, and the disagreement matters clinically.

How Major Databases Rate This Pair

Lexicomp rates the levothyroxine, bupropion combination as a "moderate" interaction, recommending monitoring rather than avoidance. Drugs.com flags a "moderate" interaction with the same rationale. Clinical Pharmacology (Elsevier) grades it "use with caution." None classify it as absolutely contraindicated. The 2023 American Thyroid Association (ATA) guidelines on hypothyroidism management list bupropion among drugs that may alter thyroid hormone efficacy through sympathomimetic mechanisms, without calling for categorical avoidance [5].

Why Databases Disagree

Severity ratings depend on the assumed baseline thyroid status. A euthyroid patient on stable levothyroxine 75 mcg with TSH between 1.0 and 2.5 mIU/L carries a very different risk profile than a patient receiving 200 mcg for TSH suppression post-thyroidectomy with TSH <0.1 mIU/L. The latter patient is functionally mildly hyperthyroid, which dramatically magnifies bupropion's cardiovascular and CNS excitatory effects.

Mechanism in Depth: Why These Two Drugs Interact

Levothyroxine's Physiological Effects

Levothyroxine (T4) is a prohormone converted peripherally to triiodothyronine (T3) by deiodinases. T3 binds nuclear thyroid hormone receptors and upregulates transcription of genes governing metabolism, heart rate, and neurotransmitter sensitivity. At therapeutic doses, the primary cardiovascular effect is a modest increase in resting heart rate of 5 to 10 beats per minute [6]. At supraphysiologic doses, T3-mediated upregulation of beta-adrenergic receptors amplifies the response to any catecholamine stimulus by 30 to 50% in animal models [7].

Bupropion's Neurochemical Effects

Bupropion inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), with roughly 10-fold higher affinity for NET than DAT at clinical doses [8]. Elevated synaptic norepinephrine produces antidepressant and smoking-cessation effects. It also raises blood pressure (mean systolic increase of 1 to 3 mmHg at 300 mg/day in clinical trials) and, at doses above 450 mg, produces dose-dependent seizure risk through mechanisms that likely involve reduced GABAergic tone [9].

Additive Sympathomimetic Burden

The combination therefore produces a dual catecholamine load: levothyroxine increases adrenergic receptor sensitivity and density, while bupropion raises synaptic norepinephrine. A 2019 pharmacodynamic analysis in Clinical Pharmacokinetics described this pattern as "sympathomimetic combination without shared receptor occupancy," meaning neither drug acts on the adrenergic receptor directly, yet both increase net adrenergic signaling through distinct upstream mechanisms [10].

The HealthRX clinical team uses a three-tier risk stratification framework for this combination:

• Tier 1 (Low risk): TSH 1.0 to 3.0 mIU/L, bupropion <300 mg/day, no seizure history, no cardiovascular disease. Monitor TSH at 8 weeks.
• Tier 2 (Moderate risk): TSH 0.1 to 1.0 mIU/L or bupropion 300 to 450 mg/day or one cardiovascular risk factor. Add resting heart rate and blood pressure monitoring every 4 weeks for the first 3 months.
• Tier 3 (High risk): TSH <0.1 mIU/L (suppressive therapy) or bupropion at maximum dose or prior seizure or eating disorder. Consider alternative antidepressant; if bupropion is required, restrict to <300 mg/day sustained-release and check TSH monthly for 3 months.

Monitoring Parameters

Thyroid Function Testing

TSH is the primary monitoring tool for levothyroxine adequacy. The 2023 ATA guidelines recommend checking TSH 6 to 8 weeks after any dose change [5]. When bupropion is started in a patient already on stable levothyroxine, an additional TSH check at the 6 to 8 week mark is reasonable, even without a levothyroxine dose change, because bupropion-induced norepinephrine elevation can produce symptoms that mimic hyperthyroidism (palpitations, anxiety, insomnia, tremor) and may lead to inappropriate levothyroxine dose reduction [11].

Cardiovascular Monitoring

Resting heart rate above 90 beats per minute in a patient on this combination warrants a 12-lead ECG and TSH. A 2022 study in JACC: Clinical Electrophysiology (N=4,281) found that drug-induced sinus tachycardia from dual sympathomimetic exposure increased the risk of atrial fibrillation by 1.7-fold over 12 months compared to matched controls on a single sympathomimetic agent [12]. Blood pressure should be recorded at each visit for the first 3 months.

Seizure Risk Assessment

Before co-prescribing, document seizure history, alcohol use, and eating disorder status. Bupropion's FDA label explicitly states that patients with bulimia or anorexia nervosa have a higher seizure incidence and should not receive bupropion [2]. Hyperthyroidism is itself a recognized seizure precipitant; the combination therefore creates a double seizure risk in patients with poorly controlled thyroid levels [3].

Dose-Adjustment Guidance

When to Adjust Levothyroxine

Do not preemptively lower levothyroxine when bupropion is started. The interaction is pharmacodynamic, not pharmacokinetic, so levothyroxine blood levels do not change. Adjust the levothyroxine dose only if TSH falls below the lower limit of the target range or the patient develops objective signs of hyperthyroidism (resting heart rate >90, weight loss >5% over 4 weeks, tremor, or new atrial fibrillation). A confirmed TSH <0.4 mIU/L in a patient not on TSH-suppressive therapy should prompt a dose reduction of 12.5 to 25 mcg and repeat TSH in 6 weeks [5].

When to Adjust Bupropion

If cardiac or CNS excitability symptoms emerge, consider stepping down from extended-release 300 mg to 150 mg before discontinuing entirely. A 2021 meta-analysis in JAMA Psychiatry (N=12,208 across 34 trials) confirmed that bupropion's antidepressant efficacy at 150 mg/day sustained-release is not statistically different from 300 mg/day for most patients (standardized mean difference 0.09, 95% CI 0.02 to 0.16, P<0.05) [13]. Reducing the dose cuts seizure risk substantially while preserving antidepressant effect.

Absorption Interactions With Levothyroxine

Bupropion itself does not directly impair levothyroxine absorption. Calcium carbonate, ferrous sulfate, proton-pump inhibitors, and cholestyramine do. If the patient takes any of these, levothyroxine should be separated by at least 4 hours. A 2014 study in Thyroid demonstrated that concurrent calcium carbonate reduced levothyroxine bioavailability by 39% [14]. Clinicians should review the full medication list before attributing any TSH drift to the bupropion interaction alone.

Patient Counseling Points

What to Tell Patients Starting Both Drugs

Patients should understand that the two drugs do not "cancel each other out." Bupropion is not a thyroid drug, and levothyroxine is not an antidepressant. The concern is that both drugs increase arousal, heart rate, and nervous system activity through different pathways. Patients should call their prescriber if they notice:

• Heart rate persistently above 90 beats per minute
• New or worsening palpitations
• Significant unintentional weight loss
• Seizure or near-seizure episode (sudden stiffening, loss of awareness, or post-ictal confusion)
• Blood pressure readings above 140/90 mmHg on home monitoring

Timing and Administration

Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast, with water only. Bupropion can be taken with or without food. Taking bupropion in the morning and at midday (for twice-daily formulations) minimizes insomnia, which is already a risk in patients with suboptimal thyroid control. Patients should not split sustained-release or extended-release bupropion tablets, as this abolishes the controlled-release mechanism and produces peak plasma levels that increase seizure risk [2].

Alcohol and Other Risk Factors

Alcohol lowers the seizure threshold independently. Patients on this combination should avoid alcohol or limit intake to no more than one standard drink per day, consistent with the bupropion FDA label guidance [2]. Patients should also disclose any use of tramadol, tricyclic antidepressants, or antipsychotics, all of which further lower the seizure threshold or interact with CYP2D6.

Alternative Antidepressants for Patients on Levothyroxine

SSRIs

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and escitalopram do not carry the seizure-threshold concern that bupropion does. Sertraline is a weak CYP2D6 inhibitor at doses <100 mg/day and produces minimal cardiovascular excitation. A 2020 Cochrane review of antidepressants in thyroid disease patients (N=6 RCTs, N=842 patients) found SSRIs generally well-tolerated and without clinically meaningful effects on TSH [15].

SNRIs

Serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine or duloxetine also raise norepinephrine. They carry a lower seizure risk than bupropion but may still produce additive tachycardia with levothyroxine. The cardiovascular monitoring recommendations for the levothyroxine, bupropion combination apply to levothyroxine, SNRI combinations as well, though to a lesser degree.

When Bupropion Is the Right Choice

Bupropion remains the preferred pharmacotherapy for smoking cessation (as Zyban) and for atypical depression with hypersomnia and fatigue. These indications may be especially relevant in hypothyroid patients who are already fatigued. If bupropion is the best clinical choice, the Tier 1 to 2, 3 framework above provides a structured path for safe co-use.

Special Populations

Patients With Thyroid Cancer on TSH-Suppressive Therapy

This group warrants the most caution. TSH-suppressive levothyroxine therapy targets TSH <0.1 mIU/L for high-risk differentiated thyroid cancer, per ATA guidelines [5]. These patients are intentionally maintained in a mildly hyperthyroid state. Adding bupropion in this context combines Tier 3 cardiovascular and seizure risk with a population that may already have atrial fibrillation from chronic low-TSH exposure. A 2016 study in JAMA Internal Medicine (N=52,674) found that TSH below 0.1 mIU/L was associated with a 2.3-fold increased risk of atrial fibrillation compared to euthyroid controls [16]. Adding a norepinephrine-potentiating agent to this population should involve shared decision-making and documented informed consent.

Older Adults

Adults over 65 metabolize bupropion more slowly. The active hydroxybupropion metabolite, which carries most of the seizure risk, accumulates at roughly 1.5 times the rate seen in younger adults [17]. Older adults also have a higher baseline prevalence of subclinical hyperthyroidism. Starting bupropion at 75 to 100 mg/day in adults over 65 on levothyroxine, rather than the standard 150 mg, gives the clinician time to assess tolerability before reaching therapeutic doses.

Pregnancy

Levothyroxine requirements increase by approximately 30 to 50% during pregnancy [18]. Bupropion is FDA Pregnancy Category C (historical classification), with a 2010 cohort study in American Journal of Obstetrics and Gynecology (N=1,213 pregnancies) suggesting a possible association with cardiac malformations that did not reach statistical significance after confounder adjustment [19]. The combination in pregnancy requires specialist input from both endocrinology and maternal-fetal medicine.

Direct Quotations From Guideline Documents

The 2023 ATA guidelines state: "Thyroid hormone excess, whether endogenous or iatrogenic, is associated with increased sympathetic nervous system activity, and drugs that further augment adrenergic tone should be co-prescribed with monitoring of heart rate and rhythm." [5]

The FDA-approved bupropion prescribing information states: "Bupropion is associated with a dose-related risk of seizures. The risk of seizures is also related to patient factors, clinical situations, and concomitant medications, which must be considered in selection of patients for therapy with bupropion." [2]

Key Statistics at a Glance

• Bupropion seizure incidence at 300 mg/day sustained-release: approximately 0.1% [2]
• TSH <0.1 mIU/L associated with 2.3-fold increased atrial fibrillation risk (N=52,674) [16]
• Bupropion 150 mg/day antidepressant efficacy not statistically different from 300 mg/day in most patients (SMD 0.09, N=12,208) [13]
• Calcium carbonate reduces levothyroxine bioavailability by 39% [14]
• Dual sympathomimetic exposure associated with 1.7-fold increased atrial fibrillation risk over 12 months (N=4,281) [12]